University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 4K-16-5


Phase II Randomized Double Blind Trial of PF 04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Sarmad Sadeghi, M.D.
Other Trial Staff:  Cheryl Kefauver, R.N., Monica Flores, D.M., Lusine Raddatz, D.M., Lagrimas Ilagan, D.M., Lagrimas Ilagan, D.M., Kristy Sartor Massopust, Coordinator, Charis Barg, Coordinator, Bartolo Santos, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.